Immunocore Holdings (IMCR) Interest & Investment Income (2021 - 2026)
Immunocore Holdings (IMCR) posted Interest & Investment Income of $3.4 million for Q1 2026, down 12.49% sequentially from $3.9 million in Q4 2025, and down 18.15% YoY from $4.2 million in Q1 2025.
Analysis
Immunocore Holdings (IMCR) Interest & Investment Income (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Interest & Investment Income for 6 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Interest & Investment Income fell 18.15% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (down 27.06% YoY) and the FY2025 annual result came in at $16.5 million, down 35.69% from the prior year.
- Interest & Investment Income declined to $3.4 million in Q1 2026 per IMCR's latest filing, from $3.9 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $8.2 million in Q1 2024 and troughed at $148599.1 in Q2 2022.
- A 5-year average of $4.2 million and a median of $4.2 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income surged 42170.33% in 2022, then plunged 49.36% in 2025.
- Over 5 years, Interest & Investment Income stood at $2.8 million in 2022, then jumped by 90.94% to $5.4 million in 2023, then dropped by 4.91% to $5.2 million in 2024, then retreated by 24.49% to $3.9 million in 2025, then fell by 12.49% to $3.4 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $3.4 million, $3.9 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Immunocore Holdings | 1.87 Bn | 985.43 Mn | 114.84 Mn | 3.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Mn |
| Mar 31, 2026 | 3.42 Mn |
| Dec 31, 2025 | 3.91 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 6.24 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 3.13 Mn |
| Dec 31, 2022 | 2.85 Mn |
| Sep 30, 2022 | 703,593.33 |
| Jun 30, 2022 | 148,599.08 |
| Dec 31, 2021 | 6,740.05 |
| Sep 30, 2021 | 11,028.67 |